整合患者教育在医疗服务提供:从优化实用性试验学习的学习
Elizabeth A Bayliss1, Kathy S Gleason2, Orla C Sheehan3
1Institute for Health Research, Kaiser Permanente Colorado, Central Support Services, 16601 East Centretech Parkway, Aurora, CO 80011, United States; Department of Family Medicine, University of Colorado School of Medicine, AO1, Mail Stop F496, Aurora, CO 80045, United States.
Patient education and counseling
|October 22, 2025
概括
患者教育是改善抑郁症患者沟通的关键. 优化干预为患者和护理合作伙伴提供了描述性教育材料,提供了各种交付偏好和时间建议,以更好地融入初级保健.
科学领域:
- 老年学是一门学科.
- 初级医疗保健医学 一级医疗保健医学
- 卫生沟通健康沟通
背景情况:
- 停止处方对于管理多药性药物至关重要,特别是在认知障碍的老年人中.
- 有效的患者和护理人员教育对于成功的抑郁症沟通和实践整合至关重要.
- 优化干预旨在解决在初级保健机构内抑郁症教育方面的差距.
研究的目的:
- 分享从开发和实施优化抑郁症描述教育干预中学到的经验教训.
- 探索患者和护理伙伴对接受抑郁症教育的观点.
- 确定在初级保健中提供抑郁症教育的最佳方法.
主要方法:
- 一个集群随机的实用试验,涉及认知障碍和多药学个体.
- 干预包括邮寄的教育材料,对照组在护理地点收到材料.
- 与患者和护理合作伙伴进行的半结构面试,使用实施评估框架方法进行分析.
主要成果:
- 患者和护理合作伙伴欢迎放弃治疗的教育材料.
- 首选的配送方式各不相同,包括在线,邮件和处方药.
- 由于竞争性需求,医疗点分销面临挑战;提供者更喜欢将交付与临床接触结合起来.
结论:
- 成功的抑郁症教育需要多个团队成员和不同的交付模式.
- 对于患者和护理伙伴来说,提供抑郁症信息的灵活和多样化的方法是必要的.
- 需要进一步调查具体的操作策略来减少教育的描述.
相关概念视频
Drug Dosing: Geriatric Patients
222
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
222
Drug Therapy
239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
239
Desensitization and Tachyphylaxis
3.0K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.0K
Antidepressant Drugs: Overview
1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
Dosage Regimens: Designs and Approaches
260
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
260
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249


